Table 1.
List of 43 Drug Combinations, Including Target and Prediction Synergy Score, Selected for High-throughput Screening
| Number in screen | Drug 1 | Drug 2 | Prediction synergy score1 |
|---|---|---|---|
| (0–520) | |||
| 1 | CGP-082996 (CDK4) | Gemcitabine (Base analogue) | 503 |
| 2 | CGP-082996 (CDK4) | Vinorelbine (Alkylating) | 426 |
| 3 | CGP-082996 (CDK4) | Obatoclax Mesylate (BCL2 and MCL1) | 400 |
| 4 | Lapatinib (EGFR and ERBB2) | Gemcitabine (Base analogue) | 424 |
| 5 | Lapatinib (EGFR and ERBB2) | Vinorelbine (Alkylating) | 403 |
| 6 | Lapatinib (EGFR and ERBB2) | Obatoclax Mesylate (BCL2 and MCL1) | 398 |
| 7 | Erlotinib (EGFR and ERBB2) | Gemcitabine (Base analogue) | 420 |
| 8 | Erlotinib (EGFR and ERBB2) | Vinorelbine (Alkylating) | 392 |
| 9 | Erlotinib (EGFR and ERBB2) | Obatoclax Mesylate (BCL2 and MCL1) | 394 |
| 10 | CGP-082996 (CDK4) | Thapsigargin (Ca2+ ATPase) | 438 |
| 11 | Lapatinib (EGFR and ERBB2) | Thapsigargin (Ca2+ ATPase) | 394 |
| 12 | Erlotinib (EGFR and ERBB2) | Thapsigargin (Ca2+ ATPase) | 390 |
| 13 | CGP-082996 (CDK4) | Tipifarnib (Farnesyl transferase) | 395 |
| 14 | CGP-082996 (CDK4) | Bleomycin (Antitumor antibiotic) | 426 |
| 15 | CGP-082996 (CDK4) | Etoposide (TOPO2) | 433 |
| 16 | CGP-082996 (CDK4) | Mitomycin C (DNA crosslinking) | 432 |
| 17 | CGP-082996 (CDK4) | Doxorubicin (Anthracyclines) | 403 |
| 18 | CGP-082996 (CDK4) | Shikonin (RSK) | 404 |
| 19 | Lapatinib (EGFR and ERBB2) | Tipifarnib (Farnesyl transferase) | 435 |
| 20 | Lapatinib (EGFR and ERBB2) | Bleomycin (Antitumor antibiotic) | 395 |
| 21 | Lapatinib (EGFR and ERBB2) | Shikonin (RSK) | 388 |
| 22 | Tipifarnib (Farnesyl transferase) | NVP-TAE684 (ALK) | 514 |
| 23 | Tipifarnib (Farnesyl transferase) | A-770041 (SRC) | 441 |
| 24 | Tipifarnib (Farnesyl transferase) | Sunitinib (PDGFR) | 405 |
| 25 | Tipifarnib (Farnesyl transferase) | Pazopanib (PDGFR) | 424 |
| 26 | Sunitinib (PDGFR) | Gemcitabine (Base analogue) | 503 |
| 27 | Pazopanib (PDGFR) | Gemcitabine (Base analogue) | 437 |
| 28 | Pazopanib (PDGFR) | BMS-536924 (HGFR) | 307 |
| 29 | Etoposide (TOPO2) | NVP-TAE684 (ALK) | 404 |
| 30 | Etoposide (TOPO2) | A-443654 (AKT 1/2/3) | 404 |
| 31 | RG7112 (MDM2) | Sunitinib (PDGFR) | Not calculated2 |
| 32 | RG7112 (MDM2) | Pazopanib (PDGFR) | Not calculated2 |
| 33 | RG7112 (MDM2) | CGP-082996 (CDK4) | Not calculated2 |
| 34 | MG-132 (Proteaome) | Vinorelbine (Alkylating) | 124 |
| 35 | PHA-665752 (MET) | NVP-LAQ824 (HDAC) | 147 |
| 36 | Thapsigargin (Ca2+ ATPase) | AP-24534 (MTOR) | 138 |
| 37 | Thapsigargin (Ca2+ ATPase) | Midostaurin (KIT) | 128 |
| 38 | WH-4-023 (SRC) | Vinorelbine (Alkylating) | 148 |
| 39 | WH-4-023 (SRC) | AUY922 (HSP90) | 140 |
| 40 | Bleomycin (Antitumor antibiotic) | OSI-906 (IGFR) | 219 |
| 41 | Bleomycin (Antitumor antibiotic) | GSK269962A (ROCK) | 216 |
| 42 | Bleomycin (Antitumor antibiotic) | A-770041 (SRC) | 135 |
| 43 | Bleomycin (Antitumor antibiotic) | WH-4-023 (SRC) | 131 |
1Prediciton synergy score is based on a logistic regression model, according to the model available at https://github.com/bartwesterman/drug-atlas;
2Predicted synergy score was not calculated due to the lack of MDM2 targeting drugs in the Cancer Drug Atlas.